APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Vaccine

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

Selected research

Market Outlook & Growth Opportunities

Global Meningococcal Vaccine Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchMeningococcal Vaccine Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Vaccine Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Meningococcal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.

Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.

Read the full market overview

In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.

This report provides an overview of the global Meningococcal Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Meningococcal Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Meningococcal Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Meningococcal Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Meningococcal Vaccine Segment by Company

Novartis

GSK

Merck

CSL

Baxter

JN International Medical Corporation

Serum Institute of India

Bio-Med

China National Biotec Group

Hualan Bio

Walvax

Zhifei

Meningococcal Vaccine Segment by Type

Meningtits A

Polysaccharide Meningtitis AC

Meningitis ACYW

Meningococcal Vaccine Segment by Application

6 Months-15Year

over 3 Year

over 2 Year

over 3 Months

Meningococcal Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Meningococcal Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Meningococcal Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Meningococcal Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Meningococcal Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Meningococcal Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Meningococcal Vaccine industry.

Chapter 3: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Meningococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Meningococcal Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Meningococcal Vaccine Industry Trends Table 2. Meningococcal Vaccine Industry Drivers Table 3. Meningococcal Vaccine Industry Opportunities and Challenges Table 4. Meningococcal Vaccine Industry Restraints Table 5. Global Meningococcal Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Meningococcal Vaccine Revenue Share by Company (2021-2026) Table 7. Global Meningococcal Vaccine Sales Volume by Company (10K Pcs) & (2021-2026) Table 8. Global Meningococcal Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Meningococcal Vaccine Average Price (USD/Pcs) of Company (2021-2026) Table 10. Global Meningococcal Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Meningococcal Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Meningococcal Vaccine Company, Product Type & Application Table 13. Global Meningococcal Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Meningococcal Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Meningtits A Table 18. Significant Companies of Polysaccharide Meningtitis AC Table 19. Significant Companies of Meningitis ACYW Table 20. Global Meningococcal Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (10K Pcs) Table 21. Global Meningococcal Vaccine Sales Volume by Type (2021-2026) & (10K Pcs) Table 22. Global Meningococcal Vaccine Sales Volume by Type (2027-2032) & (10K Pcs) Table 23. Global Meningococcal Vaccine Sales Volume Share by Type (2021-2026) Table 24. Global Meningococcal Vaccine Sales Volume Share by Type (2027-2032) Table 25. Global Meningococcal Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Meningococcal Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Meningococcal Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Meningococcal Vaccine Sales Value Share by Type (2021-2026) Table 29. Global Meningococcal Vaccine Sales Value Share by Type (2027-2032) Table 30. Significant Companies of 6 Months-15Year Table 31. Significant Companies of over 3 Year Table 32. Significant Companies of over 2 Year Table 33. Significant Companies of over 3 Months Table 34. Global Meningococcal Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (10K Pcs) Table 35. Global Meningococcal Vaccine Sales Volume by Application (2021-2026) & (10K Pcs) Table 36. Global Meningococcal Vaccine Sales Volume by Application (2027-2032) & (10K Pcs) Table 37. Global Meningococcal Vaccine Sales Volume Share by Application (2021-2026) Table 38. Global Meningococcal Vaccine Sales Volume Share by Application (2027-2032) Table 39. Global Meningococcal Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Meningococcal Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Meningococcal Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Meningococcal Vaccine Sales Value Share by Application (2021-2026) Table 43. Global Meningococcal Vaccine Sales Value Share by Application (2027-2032) Table 44. Global Meningococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032 (10K Pcs) Table 45. Global Meningococcal Vaccine Sales by Region (2021-2026) & (10K Pcs) Table 46. Global Meningococcal Vaccine Sales Market Share by Region (2021-2026) Table 47. Global Meningococcal Vaccine Sales by Region (2027-2032) & (10K Pcs) Table 48. Global Meningococcal Vaccine Sales Market Share by Region (2027-2032) Table 49. Global Meningococcal Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Meningococcal Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Meningococcal Vaccine Sales Value Share by Region (2021-2026) Table 52. Global Meningococcal Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Meningococcal Vaccine Sales Value Share by Region (2027-2032) Table 54. Global Meningococcal Vaccine Market Average Price (USD/Pcs) by Region (2021-2026) Table 55. Global Meningococcal Vaccine Market Average Price (USD/Pcs) by Region (2027-2032) Table 56. Global Meningococcal Vaccine Sales by Country: 2021 VS 2025 VS 2032 (10K Pcs) Table 57. Global Meningococcal Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Meningococcal Vaccine Sales by Country (2021-2026) & (10K Pcs) Table 59. Global Meningococcal Vaccine Sales Market Share by Country (2021-2026) Table 60. Global Meningococcal Vaccine Sales by Country (2027-2032) & (10K Pcs) Table 61. Global Meningococcal Vaccine Sales Market Share by Country (2027-2032) Table 62. Global Meningococcal Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Meningococcal Vaccine Sales Value Market Share by Country (2021-2026) Table 64. Global Meningococcal Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Meningococcal Vaccine Sales Value Market Share by Country (2027-2032) Table 66. Novartis Company Information Table 67. Novartis Business Overview Table 68. Novartis Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 69. Novartis Meningococcal Vaccine Product Portfolio Table 70. Novartis Recent Development Table 71. GSK Company Information Table 72. GSK Business Overview Table 73. GSK Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 74. GSK Meningococcal Vaccine Product Portfolio Table 75. GSK Recent Development Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 79. Merck Meningococcal Vaccine Product Portfolio Table 80. Merck Recent Development Table 81. CSL Company Information Table 82. CSL Business Overview Table 83. CSL Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 84. CSL Meningococcal Vaccine Product Portfolio Table 85. CSL Recent Development Table 86. Baxter Company Information Table 87. Baxter Business Overview Table 88. Baxter Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 89. Baxter Meningococcal Vaccine Product Portfolio Table 90. Baxter Recent Development Table 91. JN International Medical Corporation Company Information Table 92. JN International Medical Corporation Business Overview Table 93. JN International Medical Corporation Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 94. JN International Medical Corporation Meningococcal Vaccine Product Portfolio Table 95. JN International Medical Corporation Recent Development Table 96. Serum Institute of India Company Information Table 97. Serum Institute of India Business Overview Table 98. Serum Institute of India Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 99. Serum Institute of India Meningococcal Vaccine Product Portfolio Table 100. Serum Institute of India Recent Development Table 101. Bio-Med Company Information Table 102. Bio-Med Business Overview Table 103. Bio-Med Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 104. Bio-Med Meningococcal Vaccine Product Portfolio Table 105. Bio-Med Recent Development Table 106. China National Biotec Group Company Information Table 107. China National Biotec Group Business Overview Table 108. China National Biotec Group Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 109. China National Biotec Group Meningococcal Vaccine Product Portfolio Table 110. China National Biotec Group Recent Development Table 111. Hualan Bio Company Information Table 112. Hualan Bio Business Overview Table 113. Hualan Bio Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 114. Hualan Bio Meningococcal Vaccine Product Portfolio Table 115. Hualan Bio Recent Development Table 116. Walvax Company Information Table 117. Walvax Business Overview Table 118. Walvax Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 119. Walvax Meningococcal Vaccine Product Portfolio Table 120. Walvax Recent Development Table 121. Zhifei Company Information Table 122. Zhifei Business Overview Table 123. Zhifei Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 124. Zhifei Meningococcal Vaccine Product Portfolio Table 125. Zhifei Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Meningococcal Vaccine Distributors List Table 129. Meningococcal Vaccine Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Meningococcal Vaccine Product Image Figure 2. Global Meningococcal Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Meningococcal Vaccine Sales (2021-2032) & (10K Pcs) Figure 5. Global Meningococcal Vaccine Sales Average Price (USD/Pcs) & (2021-2032) Figure 6. Global Meningococcal Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Meningtits A Image Figure 10. Polysaccharide Meningtitis AC Image Figure 11. Meningitis ACYW Image Figure 12. Global Meningococcal Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (10K Pcs) Figure 13. Global Meningococcal Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Meningococcal Vaccine Sales Volume Share by Type (2021-2032) Figure 15. Global Meningococcal Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Meningococcal Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Meningococcal Vaccine Sales Value Share by Type (2021-2032) Figure 18. 6 Months-15Year Image Figure 19. over 3 Year Image Figure 20. over 2 Year Image Figure 21. over 3 Months Image Figure 22. Global Meningococcal Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (10K Pcs) Figure 23. Global Meningococcal Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Meningococcal Vaccine Sales Volume Share by Application (2021-2032) Figure 25. Global Meningococcal Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Meningococcal Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Meningococcal Vaccine Sales Value Share by Application (2021-2032) Figure 28. Global Meningococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032 (10K Pcs) Figure 29. Global Meningococcal Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Meningococcal Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Meningococcal Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Meningococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. North America Meningococcal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Meningococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Meningococcal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Meningococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Meningococcal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Meningococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. South America Meningococcal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Meningococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Meningococcal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Meningococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Meningococcal Vaccine Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Meningococcal Vaccine Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Meningtits A
  • Polysaccharide Meningtitis AC
  • Meningitis ACYW
Applications
  • 6 Months-15Year
  • over 3 Year
  • over 2 Year
  • over 3 Months
Companies covered
  • Novartis
  • GSK
  • Merck
  • CSL
  • Baxter
  • JN International Medical Corporation
  • Serum Institute of India
  • Bio-Med
  • China National Biotec Group
  • Hualan Bio
  • Walvax
  • Zhifei

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Meningococcal Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Meningococcal Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Meningococcal Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Meningococcal Vaccine Market Dynamics
  1. 2.1 Meningococcal Vaccine Industry Trends
  2. 2.2 Meningococcal Vaccine Industry Drivers
  3. 2.3 Meningococcal Vaccine Industry Opportunities and Challenges
  4. 2.4 Meningococcal Vaccine Industry Restraints
3 Meningococcal Vaccine Market by Company
  1. 3.1 Global Meningococcal Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Meningococcal Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Meningococcal Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Meningococcal Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Meningococcal Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Meningococcal Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Meningococcal Vaccine Company Product Type and Application
  8. 3.8 Global Meningococcal Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Meningococcal Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Meningococcal Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Meningococcal Vaccine Market by Type
  1. 4.1 Meningococcal Vaccine Type Introduction
  2. 4.1.1 Meningtits A
  3. 4.1.2 Polysaccharide Meningtitis AC
  4. 4.1.3 Meningitis ACYW
  5. 4.2 Global Meningococcal Vaccine Sales Volume by Type
  6. 4.2.1 Global Meningococcal Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Meningococcal Vaccine Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Meningococcal Vaccine Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Meningococcal Vaccine Sales Value by Type
  10. 4.3.1 Global Meningococcal Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Meningococcal Vaccine Sales Value by Type (2021-2032)
  12. 4.3.3 Global Meningococcal Vaccine Sales Value Share by Type (2021-2032)
5 Meningococcal Vaccine Market by Application
  1. 5.1 Meningococcal Vaccine Application Introduction
  2. 5.1.1 6 Months-15Year
  3. 5.1.2 over 3 Year
  4. 5.1.3 over 2 Year
  5. 5.1.4 over 3 Months
  6. 5.2 Global Meningococcal Vaccine Sales Volume by Application
  7. 5.2.1 Global Meningococcal Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Meningococcal Vaccine Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Meningococcal Vaccine Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Meningococcal Vaccine Sales Value by Application
  11. 5.3.1 Global Meningococcal Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Meningococcal Vaccine Sales Value by Application (2021-2032)
  13. 5.3.3 Global Meningococcal Vaccine Sales Value Share by Application (2021-2032)
6 Meningococcal Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Meningococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Meningococcal Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Meningococcal Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Meningococcal Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Meningococcal Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Meningococcal Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Meningococcal Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Meningococcal Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Meningococcal Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Meningococcal Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Meningococcal Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Meningococcal Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Meningococcal Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Meningococcal Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Meningococcal Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Meningococcal Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Meningococcal Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Meningococcal Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Meningococcal Vaccine Sales Value Share by Country, 2025 VS 2032
7 Meningococcal Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Meningococcal Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Meningococcal Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Meningococcal Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Meningococcal Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Meningococcal Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Meningococcal Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Meningococcal Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Meningococcal Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Meningococcal Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Meningococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Meningococcal Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Meningococcal Vaccine Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK Meningococcal Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Meningococcal Vaccine Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 CSL
  20. 8.4.1 CSL Company Information
  21. 8.4.2 CSL Business Overview
  22. 8.4.3 CSL Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 CSL Meningococcal Vaccine Product Portfolio
  24. 8.4.5 CSL Recent Developments
  25. 8.5 Baxter
  26. 8.5.1 Baxter Company Information
  27. 8.5.2 Baxter Business Overview
  28. 8.5.3 Baxter Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Baxter Meningococcal Vaccine Product Portfolio
  30. 8.5.5 Baxter Recent Developments
  31. 8.6 JN International Medical Corporation
  32. 8.6.1 JN International Medical Corporation Company Information
  33. 8.6.2 JN International Medical Corporation Business Overview
  34. 8.6.3 JN International Medical Corporation Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 JN International Medical Corporation Meningococcal Vaccine Product Portfolio
  36. 8.6.5 JN International Medical Corporation Recent Developments
  37. 8.7 Serum Institute of India
  38. 8.7.1 Serum Institute of India Company Information
  39. 8.7.2 Serum Institute of India Business Overview
  40. 8.7.3 Serum Institute of India Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute of India Meningococcal Vaccine Product Portfolio
  42. 8.7.5 Serum Institute of India Recent Developments
  43. 8.8 Bio-Med
  44. 8.8.1 Bio-Med Company Information
  45. 8.8.2 Bio-Med Business Overview
  46. 8.8.3 Bio-Med Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bio-Med Meningococcal Vaccine Product Portfolio
  48. 8.8.5 Bio-Med Recent Developments
  49. 8.9 China National Biotec Group
  50. 8.9.1 China National Biotec Group Company Information
  51. 8.9.2 China National Biotec Group Business Overview
  52. 8.9.3 China National Biotec Group Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 China National Biotec Group Meningococcal Vaccine Product Portfolio
  54. 8.9.5 China National Biotec Group Recent Developments
  55. 8.10 Hualan Bio
  56. 8.10.1 Hualan Bio Company Information
  57. 8.10.2 Hualan Bio Business Overview
  58. 8.10.3 Hualan Bio Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Hualan Bio Meningococcal Vaccine Product Portfolio
  60. 8.10.5 Hualan Bio Recent Developments
  61. 8.11 Walvax
  62. 8.11.1 Walvax Company Information
  63. 8.11.2 Walvax Business Overview
  64. 8.11.3 Walvax Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Walvax Meningococcal Vaccine Product Portfolio
  66. 8.11.5 Walvax Recent Developments
  67. 8.12 Zhifei
  68. 8.12.1 Zhifei Company Information
  69. 8.12.2 Zhifei Business Overview
  70. 8.12.3 Zhifei Meningococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Zhifei Meningococcal Vaccine Product Portfolio
  72. 8.12.5 Zhifei Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Meningococcal Vaccine Value Chain Analysis
  2. 9.1.1 Meningococcal Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Meningococcal Vaccine Sales Mode & Process
  6. 9.2 Meningococcal Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Meningococcal Vaccine Distributors
  9. 9.2.3 Meningococcal Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst